Thu Jan 09 07:10:00 UTC 2025: **FDA’s Proposed Nicotine Reduction in Cigarettes Sparks Concerns Over Black Market Boom**

Washington D.C. – The Food and Drug Administration (FDA) is moving forward with a plan to drastically reduce nicotine levels in cigarettes, a move that has sparked significant controversy. While the FDA argues this will curb addiction and benefit public health, critics warn it could significantly boost the black market for tobacco products, empowering criminal organizations.

The proposed rule, which has completed regulatory review, would effectively ban currently available cigarettes in favor of low-nicotine alternatives. Rich Marianos, former assistant director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, voiced strong concerns, stating the ban would be a “gift” to cartels, increasing violence and undermining efforts to reduce smoking. He points to Mexican, Chinese, and Russian criminal organizations as prime beneficiaries, well-positioned to fill the demand for higher-nicotine cigarettes.

Marianos argues that the FDA failed to adequately consider the potential consequences of this policy, neglecting to consult with law enforcement and other relevant stakeholders. He predicts that the move will not deter smoking but instead drive consumers towards unregulated and potentially dangerous black market sources, increasing health risks and jeopardizing public safety.

This concern is echoed by bipartisan lawmakers who have previously highlighted the national security threat posed by tobacco trafficking, linking it to money laundering, human trafficking, and other serious crimes. The proposed rule has drawn comparisons to the administration’s previous, now-delayed attempt to ban menthol cigarettes, which faced similar opposition over potential impacts on minority communities and the black market.

While the FDA maintains the rule, once finalized, would represent a landmark public health measure, the looming prospect of a thriving black market and the potential for increased criminal activity casts a significant shadow on the initiative. The White House has yet to respond to requests for comment. The FDA has stated it cannot comment further until the rule is officially published.

Read More